NexMed Expands Scientific Advisory Board with Appointment of Key Industry Leaders
May 06 2010 - 3:45PM
Business Wire
NexMed, Inc. (Nasdaq: NEXM), a specialty CRO and a developer of
products based on the NexACT® technology, today announced the
appointments of Jack A. Reynolds, Ph.D and Daniel R. Salomon, M.D.,
to its newly formed Scientific Advisory Board (SAB), expanding the
SAB to four members.
Dr. Bassam Damaj, President and Chief Executive Officer of
NexMed, noted, “We are delighted to welcome Jack and Dan to our
SAB. Our ability to recruit such key leaders in the scientific and
medical industries is a testament to the strength of our technology
and product pipeline. Both Jack and Dan are distinguished leaders
in their respective fields. We look forward to benefiting from
their guidance going forward.”
Dr. Reynolds is currently Principal of JA Reynolds &
Associates and General Managing Partner of Pharma Capital Partners,
a private equity fund focused on the development of early-stage
pharmaceutical assets. Dr. Reynolds spent a total of almost 18
years with the Pfizer Global Research and Development division, and
over 30 years in the pharmaceutical industry. Until August 2006, he
was Senior Vice President of Research and Development and Worldwide
Head of Safety Sciences and Comparative Medicine. During his
lengthy career, Dr. Reynolds has held leadership positions of
increasing responsibility at Bristol-Myers Squibb, Bayer and
Pfizer. He was also the Founding Director of the Center for
Molecular Safety Sciences, a joint collaboration between the
non-profit Hamner Center for Molecular Safety Sciences, Duke
University and the University of North Carolina.
Dr. Salomon is currently medical director of the Center for
Organ and Cell Transplantation for Scripps Health at Scripps Green
Hospital and is an associate professor in the department of
molecular and experimental medicine at The Scripps Research
Institute. He currently serves as Chairman of the Tissue
Engineering Committee for the American Society of Gene and Cell
Therapy (ASGCT). Dr. Salomon’s research interests include; the
investigation of how molecular mechanisms driving immune cell
activation and tissue injury are regulated at the gene
transcriptional and proteomic level and mapping molecular networks
that relate to clinical outcomes in cell and organ transplantation.
Dr. Salomon previously held the position of chair of the U.S. Food
and Drug Administration's Biological Response Modifiers Advisory
Committee and has served on multiple NIH study sections and special
emphasis panels for over 15 years.
About NexMed:
NexMed is the largest specialty CRO based in San Diego, CA and
is one of the industry's most experienced CROs for in vitro and in
vivo pharmacology services and research models. The Company's goal
is to generate revenues from the growth of its Discovery
Pre-clinical CRO business, while aggressively seeking to monetize
its proprietary NexACT drug delivery technology through
out-licensing agreements with pharmaceutical and biotechnology
companies, worldwide. At the same time, NexMed has embarked on a
partnering program to pair the NexACT delivery technology with
drugs and drug candidates marketed and being developed by others,
including NexACT-based treatments for onychomycosis, psoriasis,
sexual dysfunction and cancer. For further information, go to
www.nexmed.com and www.bio-quant.com.
Nexmed (MM) (NASDAQ:NEXM)
Historical Stock Chart
From May 2024 to Jun 2024
Nexmed (MM) (NASDAQ:NEXM)
Historical Stock Chart
From Jun 2023 to Jun 2024
Real-Time news about Nexmed (MM) (NASDAQ): 0 recent articles
More NexMed, Inc. News Articles